Traore, Abdouramane and Guindo, Merepen A. and Konate, Drissa and Traore, Bourama and Diakite, Seidina A. and Kante, Salimata and Dembele, Assitan and Cisse, Abdourhamane and Incandela, Nathan C. and Kodio, Mamoudou and Coulibaly, Yaya I. and Faye, Ousmane and Kajava, Andrey V. and Pratesi, Federico and Migliorini, Paola and Papini, Anna Maria and Pacini, Lorenzo and Rovero, Paolo and Errante, Fosca and Diakite, Mahamadou and Arevalo-Herrera, Myriam and Herrera, Socrates and Corradin, Giampietro and Balam, Saidou (2022) Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas. FRONTIERS IN IMMUNOLOGY, 13: 856033. ISSN 1664-3224,
Full text not available from this repository. (Request a copy)Abstract
Despite the global interest and the unprecedented number of scientific studies triggered by the COVID-19 pandemic, few data are available from developing and low-income countries. In these regions, communities live under the threat of various transmissible diseases aside from COVID-19, including malaria. This study aims to determine the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroreactivity of antibodies from COVID-19 and pre-COVID-19 samples of individuals in Mali (West Africa). Blood samples from COVID-19 patients (n = 266) at Bamako Dermatology Hospital (HDB) and pre-COVID-19 donors (n = 283) from a previous malaria survey conducted in Dangassa village were tested by ELISA to assess IgG antibodies specific to the full-length spike (S) protein, the receptor-binding domain (RBD), and the receptor-binding motif (RBM436-507). Study participants were categorized by age, gender, treatment duration for COVID-19, and comorbidities. In addition, the cross-seroreactivity of samples from pre-COVID-19, malaria-positive patients against the three antigens was assessed. Recognition of the SARS-CoV-2 proteins by sera from COVID-19 patients was 80.5% for S, 71.1% for RBD, and 31.9% for RBM (p < 0.001). While antibody responses to S and RBD tended to be age-dependent, responses to RBM were not. Responses were not gender-dependent for any of the antigens. Higher antibody levels to S, RBD, and RBM at hospital entry were associated with shorter treatment durations, particularly for RBD (p < 0.01). In contrast, higher body weights negatively influenced the anti-S antibody response, and asthma and diabetes weakened the anti-RBM antibody responses. Although lower, a significant cross-reactive antibody response to S (21.9%), RBD (6.7%), and RBM (8.8%) was detected in the pre-COVID-19 and malaria samples. Cross-reactive antibody responses to RBM were mostly associated (p < 0.01) with the absence of current Plasmodium falciparum infection, warranting further study.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | B-CELL ACTIVATION; NEUTRALIZING ANTIBODIES; SARS-COV-2; INFECTION; TRANSMISSION; RESPONSES; IMMUNITY; ACE2; SARS-CoV-2 S protein; seroreactivity; COVID-19 samples; cross-reactivity; Pre-COVID-19 samples; malaria endemic-area |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Nephrologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Feb 2024 15:35 |
| Last Modified: | 27 Feb 2024 15:35 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58118 |
Actions (login required)
 |
View Item |
